The stock of Dexcom Inc (DXCM) has gone up by 4.29% for the week, with a 20.45% rise in the past month and a 14.54% rise in the past quarter. The volatility ratio for the week is 3.27%, and the volatility levels for the past 30 days are 3.46% for DXCM.. The simple moving average for the past 20 days is 8.44% for DXCM’s stock, with a 22.66% simple moving average for the past 200 days.
Is It Worth Investing in Dexcom Inc (NASDAQ: DXCM) Right Now?
The price-to-earnings ratio for Dexcom Inc (NASDAQ: DXCM) is 106.76x, which is above its average ratio. Moreover, the 36-month beta value for DXCM is 1.19. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 8 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DXCM is 377.37M and currently, short sellers hold a 4.41% of that float. On March 27, 2024, DXCM’s average trading volume was 3.04M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM)’s stock price has gone decline by -0.12 in comparison to its previous close of 140.10, however, the company has experienced a 4.29% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-26 that Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with RBC Capital Mkts repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to RBC Capital Mkts is $165 based on the research report published on March 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $131. The rating they have provided for DXCM stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Raymond James gave a rating of “Strong Buy” to DXCM, setting the target price at $138 in the report published on April 17th of the previous year.
DXCM Trading at 12.05% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.67% of loss for the given period.
Volatility was left at 3.46%, however, over the last 30 days, the volatility rate increased by 3.27%, as shares surge +21.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.94% upper at present.
During the last 5 trading sessions, DXCM rose by +4.29%, which changed the moving average for the period of 200-days by +15.52% in comparison to the 20-day moving average, which settled at $130.27. In addition, Dexcom Inc saw 12.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Stern Sadie, who sale 4,137 shares at the price of $140.00 back on Mar 25 ’24. After this action, Stern Sadie now owns 76,304 shares of Dexcom Inc, valued at $579,180 using the latest closing price.
Dolan Matthew Vincent, the EVP Strategy & Corp Dev of Dexcom Inc, sale 4,203 shares at $130.21 during a trade that took place back on Mar 15 ’24, which means that Dolan Matthew Vincent is holding 44,367 shares at $547,259 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Dexcom Inc stands at 0.15. The total capital return value is set at 0.13. Equity return is now at value 25.78, with 9.29 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 1.25. The interest coverage ratio of the stock is 30.52.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 2.57. When we switch over and look at the enterprise to sales, we see a ratio of 15.45. The receivables turnover for the company is 3.67for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.84.
Conclusion
To wrap up, the performance of Dexcom Inc (DXCM) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
